Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treosulfan - Medac

Drug Profile

Treosulfan - Medac

Alternative Names: CB 2562; CB 40067; CCRIS 2781; Dihydroxybusulphan; HSDB 6963; NSC 39069; Ovastat

Latest Information Update: 13 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medac
  • Developer Center for International Blood and Marrow Transplant Research; Fondazione San Raffaele; Medac
  • Class Antineoplastics; Butylene glycols; Mesylates; Small molecules
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ovarian cancer
  • Phase III Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase II Haematological malignancies; Haemoglobinopathies; Immunodeficiency disorders; Inborn error metabolic disorders; Precursor cell lymphoblastic leukaemia-lymphoma
  • Clinical Phase Unknown Cancer
  • No development reported Renal cell carcinoma; Small cell lung cancer; Solid tumours
  • Discontinued Malignant melanoma

Most Recent Events

  • 06 Mar 2019 Clinical trials in Cancer (In adults, In children, In adolescents, In infants) in Canada (IV) before March 2019
  • 06 Mar 2019 Health Canada authorise distribution of treosulfan under the Special Access Program as a conditioning agent used prior to stem cell transplantation in malignant and non-malignant diseases inn adults and paediatric patients
  • 06 Mar 2019 Medexus Pharmaceuticals announces intention to file regulatory application to Health Canada for malignant and non-malignant cancer in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top